Atlas Trials

Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Clinical trial NCT06591910 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06591910
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Unresectable Stage III Non-small-cell Lung Cancer
Start date
2024-09-20
Primary completion
2026-09-20
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.